Study to correlate between antenatal neuroprophylaxis administration timing and perinatal outcome by measuring the cord blood magnesium levels
Not Applicable
- Conditions
- Health Condition 1: R00-R99- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
- Registration Number
- CTRI/2021/01/030808
- Lead Sponsor
- Kasturba Hospital Manipal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a) Women at risk of preterm delivery between 26 weeks to 33 weeks 6 days.
b) 1st sample of multiple gestation to avoid over representing of cases.
c) PPROM ( Preterm pre labour rupture of membranes )
d) Women at risk for preterm and having preeclampsia and will be receiving neuroprophylaxis regimen.
Exclusion Criteria
a) Women who could not receive neuroprophylaxis and had delivery due to other obstetrics causes.
b) If women with risk for preterm are also having eclampsia and they have received a different regimen.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways mediate antenatal magnesium sulphate's neuroprotection in preterm infants?
How does timing of magnesium sulphate administration compare to standard-of-care protocols in preterm birth neuroprotection?
Do umbilical cord blood magnesium levels predict perinatal outcomes in CTRI/2021/01/030808 preterm infants?
What adverse events are associated with antenatal magnesium sulphate timing in preterm birth management?
Are there combination therapies with magnesium sulphate improving neuroprotection in preterm deliveries?